OYLER JOHN — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

OYLER JOHN has filed 5 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $71.71M.

Profile

John Oyler is the Chief Executive Officer and a Director of BeOne Medicines Ltd., a biotechnology company specializing in oncology therapeutics. Under his leadership, BeOne has focused on a unique CRO-free strategy to conduct global clinical trials and has achieved significant revenue through its core drug, Brukinsa.

Board memberships

• BeOne Medicines Ltd.

Awards & honors

• CEO of BeOne Medicines Ltd.
• Led the company to a successful IPO on the Hong Kong exchange
• Developed Brukinsa as a key revenue driver

Recent Transactions

Companies — Last 90 Days

• BeOne Medicines Ltd. (ONC) — 5 filings, last 2026-07-15

Frequently Asked Questions

Who is OYLER JOHN?

John Oyler is the Chief Executive Officer and a Director of BeOne Medicines Ltd., a biotechnology company specializing in oncology therapeutics. Under his leadership, BeOne has focused on a unique CRO-free strategy to conduct global clinical trials and has achieved significant revenue through its core drug, Brukinsa.…

How many SEC Form 4 filings has OYLER JOHN submitted recently?

5 primary Form 4 filings in the last 90 days, covering 1 company.

Has OYLER JOHN been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 50 open-market sales ($71.71M) across all tracked filings.

Where can I see all of OYLER JOHN's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

• What is SEC Form 4?
• How to read insider buying signals
• Understanding Rule 10b5-1 trading plans
• Browse all insiders
• Most active insiders this week